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Metabolic characterization of 
directly reprogrammed renal 
tubular epithelial cells (iRECs)
Simon Lagies1,2,3, Roman Pichler4, Michael M. Kaminski4, Manuel Schlimpert1,2,3, Gerd 
Walz4,5, Soeren S. Lienkamp  4,5 & Bernd Kammerer1,5
Fibroblasts can be directly reprogrammed to induced renal tubular epithelial cells (iRECs) using four 
transcription factors. These engineered cells may be used for disease modeling, cell replacement 
therapy or drug and toxicity testing. Direct reprogramming induces drastic changes in the 
transcriptional landscape, protein expression, morphological and functional properties of cells. 
However, how the metabolome is changed by reprogramming and to what degree it resembles the 
target cell type remains unknown. Using untargeted gas chromatography-mass spectrometry (GC-
MS) and targeted liquid chromatography-MS, we characterized the metabolome of mouse embryonic 
fibroblasts (MEFs), iRECs, mIMCD-3 cells, and whole kidneys. Metabolic fingerprinting can distinguish 
each cell type reliably, revealing iRECs are most similar to mIMCD-3 cells and clearly separate from MEFs 
used for reprogramming. Treatment with the cytotoxic drug cisplatin induced typical changes in the 
metabolic profile of iRECs commonly occurring in acute renal injury. Interestingly, metabolites in the 
medium of iRECs, but not of mIMCD-3 cells or fibroblast could distinguish treated and non-treated cells 
by cluster analysis. In conclusion, direct reprogramming of fibroblasts into renal tubular epithelial cells 
strongly influences the metabolome of engineered cells, suggesting that metabolic profiling may aid in 
establishing iRECs as in vitro models for nephrotoxicity testing in the future.
The growing incidence of chronic kidney disease leads to various socio-economic implications and represents 
a major challenge for health care systems worldwide1. There is an unmet demand for new in vitro models of 
kidney diseases to develop new diagnostic and therapeutic methods and to get a better insight into molecular 
mechanisms of kidney diseases. In the last decade, enormous progress has been made in generating kidney cells 
in vitro, including the in vitro expansion of nephron progenitors2,3, directed differentiation of induced pluripotent 
stem cells (iPSCs)4–7 and direct reprogramming8,9. These approaches have the potential to circumvent some of 
the disadvantages of primary kidney cells in culture, such as dedifferentiation, limited proliferative capacity and 
senescence10–12. Moreover, newly generated kidney cells resemble their native counterparts and share more char-
acteristics with primary kidney cells than immortalized kidney-derived cell lines like IMCD-3 or HK-2 cells13. 
Therefore, these cells can be established as reliable in vitro systems for drug toxicity testing and disease modeling. 
Furthermore, in vitro generated kidney cells could represent a patient-specific source for future cell replacement 
therapies5.
Direct reprogramming is an established approach to convert one cell type into another differentiated cell type 
bypassing the pluripotent state of iPSCs and the risks associated with this approach. Already accomplished for 
hepatocytes14,15, neurons16, cardiomyocytes17 and others, we recently managed to directly reprogram fibroblasts 
to induced renal tubular epithelial cells (iRECs) by forced expression of four transcription factors8. By lentiviral 
transduction of Hnf1β, Hnf4α, Pax8 and Emx2 fibroblasts were converted into iRECs, which exhibit distinct 
features of differentiated tubular epithelial cells. In contrast to fibroblasts, iRECs express epithelial and tubular 
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surface markers and tubule-specific transporters. Using transcriptional profiling techniques and CellNet18- based 
characterization, we demonstrated that iRECs bear a substantial similarity to primary kidney tubule cells. On 
an ultra-structural level, they show tight junctions, a clear apico-basal polarity and a basement-membrane like 
matrix. Importantly, expression of proximal-tubule specific transporters like OCT2 (SLC22A2, organic cation 
transporter-2) and the apolipoprotein-receptor megalin (LRP2), detection of microvilli and evidence for endocy-
totic uptake of albumin indicate that iRECs share specific characteristics of proximal tubule cells.
Although iRECs have been analyzed at a morphological and functional level, little is known about metabolic 
changes that occur in reprogrammed cells. Several studies have dealt with metabolome profiling of induced pluri-
potent stem cells19–22. Bioenergetics analysis of iPSCs revealed that transition from a somatic state to pluripotency 
was accompanied by a switch from mitochondrial oxidative phosphorylation to glycolytic ATP production19. 
Interestingly, the inhibition of glycolysis prevented iPSC reprogramming. These findings could be confirmed by 
an independent study using an untargeted metabolomic approach20. Comparing iPSCs to human ESCs (embry-
onic stem cells) and somatic cells (fibroblasts) demonstrated that the metabolic signature of iPSCs resembles 
that of hESCs23. This demonstrates that cellular reprogramming is accompanied by metabolic reprogramming. 
Recently, the analysis of fully and partially reprogrammed human iPSCs uncovered that the metabolic profile of 
iPSCs reflected their grade of immaturity22. These studies demonstrate that major changes in cell metabolism are 
not only characteristic of reprogramming, but also play a crucial role in the reprogramming process itself. To our 
knowledge, no studies have analyzed metabolic features of directly reprogrammed or iPSC-derived kidney cells.
One important application of directly reprogrammed cells could be their use in drug monitoring, toxicity test-
ing of novel compounds and prediction of drug toxicity on a personalized, patient-specific level. We previously 
demonstrated that iRECs are susceptible to nephrotoxic substances like gentamicin and tacrolimus8, showing 
elevated rates of cell death compared to MEFs and upregulation of Kidney injury molecule 1 (KIM1). Notably, 
there was also an iREC- specific cytotoxic response to cisplatin (cis-diamminedichloroplatinum II), which could 
not be detected in MEFs.
Cisplatin is one of the most widely applied chemotherapeutic drugs for the treatment of malignancies like 
carcinomas and germline tumors. However, like many chemotherapeutic drugs, cisplatin has several relevant 
side effects, including ototoxicity, myelosuppression, peripheral neuropathy and anaphylaxis24. Due to the accu-
mulation in renal tissue, the kidneys are especially susceptible to cisplatin, and nephrotoxicity represents a major, 
dose-limiting side effect25,26. Cisplatin-mediated toxic damage often leads to acute kidney injury (AKI), induced 
by proximal tubular injury, oxidative stress, vascular injury and inflammation24. The S3 segment of the renal prox-
imal tubule, which is mainly located in the kidney medulla, is particularly sensitive to nephrotoxic substances27. 
Uptake of cisplatin is mediated by organic cation transporter-2 (OCT2), on the basolateral side of proximal tubule 
cells28. OCT2 is also expressed in iRECs8. After uptake, cisplatin is converted into reactive metabolites29. By form-
ing DNA intra- and interstrand cross-links30, it mainly interferes with DNA synthesis and targets rapidly pro-
liferating cells. Following cisplatin- induced DNA damage and DNA damage repair (DDR), multiple molecular 
pathways are activated, such as p53 signaling31, apoptosis pathways, autophagy32 and TNFα expression33. These 
processes, including mitochondrial dysfunction and activation of the mitochondrial apoptotic pathway34, have 
various implications for the transcriptome, proteome and metabolome of affected cells35.
Consequently, several studies aimed at analyzing cisplatin-induced metabolic alterations in cells treated 
with cisplatin27,35–41. There is a known depletion of amino acids in tubular cells after cisplatin application, 
mainly caused by elevated levels of aminoaciduria and deteriorated reabsorption of amino acids27,36,37. Notably, 
branched-chain amino acids like leucine, isoleucine and valine are elevated in urine and decreased in serum, and 
could be used as biomarkers to assess individual predisposition for nephrotoxicity as they correlate with common 
markers for renal function after cisplatin exposure39. Moreover, cisplatin impacts lipid metabolism and leads to an 
accumulation of fatty acids in kidney tissue, due to reduced fatty acid oxidation35,37,42. Furthermore, diacylglycer-
ols, triacylglycerols, ceramides and in general neutral lipids accumulate upon cisplatin application27,43. In addition 
to alterations in lipid metabolism, cisplatin has also been shown to reduce enzymes involved in glycolysis44. Thus, 
glucose accumulates by cisplatin application and metabolites involved in glycolysis decrease45.
In this study, we analyzed iRECs, mIMCD-3 cells, MEFs and whole kidneys with an untargeted metabolomic 
approach. Analyzing the endo- and exometabolome by gas chromatography-mass spectrometry (GC-MS), each 
cell type could be reliably distinguished. iRECs cluster with mIMCD-3 cells but clearly separate from MEFs, indi-
cating that the metabolic profile of iRECs is similar to the profile of mIMCD-3 cells. Treatment with the chemo-
therapeutic drug cisplatin affected the metabolome of iRECs and mIMCD-3 cells, whereas no changes could be 
elicited in MEFs. In iRECs and mIMCD-3 cells cisplatin administration led to a decrease of several clusters of 
metabolites, including amino acids, metabolites involved in glycolysis and the pentose monophosphate pathway, 
and TCA cycle intermediates. Interestingly, we could detect several well described changes after cisplatin expo-
sure in iRECs, which could not be confirmed in mIMCD-3 cells. In particular, there was an increase of medium- 
and large-chain fatty acids in the cell and an increase of amino acids in the exometabolome.
Material and Methods
Animals. For whole kidney metabolomic analysis kidneys of three adult C57BL/6 N mice were used. After 
excision with a scalpel blade, kidneys were weighed and directly prepared for further metabolomic analysis. Mice 
were housed in a SPF facility with free access to chow and water and a 12 h day/night cycle. All animal experi-
ments were conducted according to the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals, as well as the German law for the welfare of animals, and were approved by the local authorities 
(Regierungspräsidium Freiburg). MEFs were generated as previously described8.
Cell culture. iRECs were generated by direct reprogramming of mouse embryonic fibroblasts (MEFs) as 
described previously8. In short, KspCre reporter MEFs were transduced with four lentivirus, each containing 
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one of the four transcription factors Hnf1b, Hnf4a, Emx2 and Pax8 cloned into the pWPXLd lentiviral vector 
(Addgene no. 12258). Virus concentrate was diluted 1:1000 to 1:100 in MEFM containing 8 µg ml−1 Polybrene (sc-
134220). Cells were incubated for 12 h on 7 consecutive days. 14 days after the last viral transduction GFP-positive 
cells were sorted using a BD FACSAriaTM Fusion flow cytometer (Becton Dickinson). Afterwards, the cells were 
expanded in MEFM (Dulbecco’s modified Eagle’s medium (DMEM), 2 mM L-glutamine, penicillin/streptomycin, 
10% fetal bovine serum (FBS)). All cells were cryoconserved in freezing medium (containing 50% MEFM, 40% 
FBS, 10% DMSO) and stored in liquid nitrogen.
For metabolomic analysis MEFs, iRECs and mIMCD-3 (ATTC) cells were thawed and counted. 2· 106 cells 
were seeded per 10 cm culture dish and expanded until harvested. All three cell lines were grown in MEFM 
containing DMEM High Glucose (4,5 g L−1). Medium was changed on a daily basis; the medium for metabo-
lomic analysis was incubated on cells for 24 h before harvesting. For cisplatin exposure, all three cell lines were 
incubated in MEFM containing 6 µL mL−1 cisplatin for 24 h (Cisplatin stock solution 0,1 mg mL−1, Apotheke des 
Universitätsklinikums Freiburg).
Metabolite extraction. Cells were washed twice on ice with 5 mL 0.9% NaCl. Metabolism was quenched 
by adding 1.5 mL ice-cold extraction medium, i.e. methanol/water (9/1 v/v) containing 1 µg mL−1 ribitol and 
phenyl-beta-D-glucopyranoside as internal standards. Cells were harvested by scratching them off with cell 
scrapers and transferred into 2 mL screw-cup vials prefilled with 300 mg glass beads and immediately frozen in 
liquid nitrogen. Cells were lyzed by a Precellys 24 tissue homogenizer by applying three cycles of 15 s maximal 
intensity and 10 s break at −20 °C. After centrifugation (21,000 g, 4 °C, 10 min), 550 µL of the supernatant were 
transferred in a new 2 mL Eppendorf tube and dried overnight in an Eppendorf Concentrator plus vacuum rota-
tor. Metabolite pellets were stored under nitrogen atmosphere until derivatization.
Kidneys were weighed and washed with 0.9% NaCl. The whole kidneys were transferred into screw-cup vials 
prefilled with 300 mg glass beads and quenched with extraction medium. The volume was adjusted to tissue 
weight to yield equal concentrations (see supplementary Table S1). Kidneys were lyzed by a Precellys 24 tissue 
homogenizer by applying three cycles of 30 s maximal intensity and 30 s break at −20 °C twice, with five minutes 
between the two runs. Lysates were centrifuged (21,000 g, 4 °C, 10 min) and 100 µL were dried in an Eppendorf 
Concentrator plus vacuum rotator.
Medium was centrifuged (5 min, 20,000 g, 4 °C) to remove detached or dead cells. 100 µL medium were added to 
900 µL ice-cold acetonitrile/methanol (3/1 v/v) containing 1 µg mL−1 ribitol and phenyl-beta-D-glucopyranoside 
as internal standards. After 10 s of vortexing, the medium was centrifuged (1 h, 20,000 g, 4 °C) and 100 µL of the 
supernatant were transferred to a new 2 ml Eppendorf tube and dried for three hours.
Derivatization. Metabolite pellets gained from cells, tissue or medium were derivatized by methoxymeth-
ylation of keto- and aldehyde-groups as well as trimethylsilylation of amines, hydroxyl- and carboxylic groups. 
Therefor, 20 µL methoxyamine hydrochloride (20 mg mL−1 in pyridine) were added to the metabolite pellet and 
shaken for 90 min at 28 °C with 1200 rpm. Afterwards, 50 µL N-methyl-N-(trimethylsilyl)-trifluoroacetamide 
were added and incubated for 30 min at 37 °C with 1200 rpm.
GC/MS-Analysis. 1 μL of the derivatized sample was splitlessly injected by a Gerstel MPS2 XL autosampler 
into an Agilent 7890 A/5975 C system in randomized order (sample order is shown in supplementary Table S2). 
Chromatographic separation was performed using an HP5-MS column (5%-diphenyl-95%-dimethylpolysiloxane, 
60 m x 0.25 mm × 0.25 μm). The gradient was 80 °C hold for 3 min, to 320 °C with 5 °C/min and hold for 14 min. 
The carrier gas flow rate (He) was set to 1 mL min−1 and the septum purge flow was 3 mL min−1. Spectra were 
acquired in full scan mode with a scan rate of 1.99 s−1 from 50 m/z to 800 m/z. Equilibration time and post run 
time was 1 min each. The inlet temperature was 230 °C, the MS source temperature 230 °C and the quadrupole 
analyzer temperature 150 °C.
LC/MS-Analysis. Cells or medium pellets were resuspended in 100 µL resuspension buffer (10 mM 
NH4CH3CO2 pH 9, acetonitrile/water 1/1). 5 µL were injected onto a BEH Amide 150 × 2.1 mm column. The 
column temperature was set to 40 °C. Two targeted methods were applied: one targeting amino acids, the other 
one targeting intermediates of glycolysis and the TCA-cycle. Buffer A consisted of 10 mM NH4CH3CO2 pH 
9 acetonitrile/water 20/80 and buffer B of 10 mM NH4CH3CO2 pH 9 acetonitrile/water 95/5. The chromato-
graphic program for amino acid separation was 99.9% B for 0.5 min, to 80% B until 0.6 min, to 25% B until 
5 min, hold until 8 min, to 99.9% B until 8.5 min and hold until 12 min. Separating intermediates of glycoly-
sis and the TCA-cycle was achieved by the following program: 99.9% B hold for 1 min, to 30% B until 5 min, 
to 25% B until 5.5 min hold until 8.5 min, to 99.9% B until 9 min and hold until 14 min. Each flow rate was 
set to 400 µL min−1. Multiple-Reaction-Monitoring (MRM) was optimized for each compound with analytical 
standards using Agilent’s MRM-Optimizer. All transitions are displayed in supplementary Table S3. Instrument 
parameters (6460 triple quadrupole Agilent Technologies) were set to 350 °C gas temperature, 8 L min−1 gas flow, 
30 psi nebulizer pressure, 250 °C sheath gas temperature, 5 L min−1 sheath gas flow, +3 kV/−3.5 kV capillary 
voltage and +500 V/−300 V nozzle voltage. As internal standards, 13C3-pyruvic acid, d4-succinic acid and 13C4-
15N-aspartic acid were used for intermediates of energy metabolism and amino acids, respectively. The results of 
methodology validation are displayed in supplementary Table S4.
Data analysis. Within the GC/MS sample set, there was one C10-C40 n-alkane standard sample for building 
system independently Kováts’ retention index (RI)46.
Automated Mass spectral Deconvolution and Identification System (AMDIS)47 was used for retention index 
calculation, peak identification, deconvolution and integration. A compound matrix was generated by spectcon-
nect online tool48 with compounds found in more than 50% of the replicates and an 80% similarity threshold 
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of mass spectra. We applied these rather loose settings purposely in order not to miss too many cell type spe-
cific metabolites essential to establish cellular metabolic identity. Compounds were annotated by matching the 
obtained spectra with library spectra of Nist1449, FiehnLib50 and golmDB51, where a match factor threshold of 
750 and a retention index deviation of less than 5% were applied. Annotated compounds were normalized to 
phenyl-glucose. Further, all compounds were normalized to the sum of all compounds to take different cell num-
bers and mass into account52. For cells, blank plates treated equally as plates containing cells were analyzed the 
same way and their average intensity of each compound was subtracted from each compound in each condition.
For LC/MS analysis, metabolites were identified by Quantitative Analysis software (Agilent) using retention time 
and specific MRM-transitions as well as their qualifier ratios. Data were normalized to the isotopically labeled stand-
ard according to the corresponding pathway. For cells, averaged blank values were subtracted from each metabolite.
For statistical analysis, metaboanalyst 3.053–58, an R based statistic suit for metabolomics, was used. Half of the 
minimum positive value of each metabolite replaced missing values in GC/MS analysis. In this study, following tests 
were performed: ANalysis Of VAriance (ANOVA), Benjamini-Hochberg false discovery rate with a q-value cut-off 
of 0.05, principal component analysis and heat map generation both including range-scaling (mean-centered and 
divided by the range of each variable), cluster and distance analysis after Pearson and Ward, pathway analysis as well 
as Very ImPortant feature (VIP)-plot calculation. A VIP-score above 1 was considered as meaningful.
Data availability. The dataset with every replicate for endometabolite and exometabolite analysis of this 
study is shown in supplementary Table S5.
Results
Endometabolic profiling of transdifferentiated kidney cells revealed similar fingerprints to 
immortalized kidney cells and primary kidneys. To investigate the metabolic identity of iRECs in com-
parison to other renal epithelial cells and cells they were derived from (MEFs), cultured iRECs, mIMCD-3 cells, 
MEFs and whole adult kidney lysates were analyzed by untargeted GC/MS based metabolic profiling. Principle 
component analysis (PCA) revealed that principle component (PC) 1 discriminated between primary renal tissue 
(positive PC1) and cell culture (negative PC1) with 53.2% of the observed differences (Fig. 1a.) PC 2 accounted for 
13.9% of the alterations and distinguished fibroblasts (positive PC2) from kidney cells (negative PC2). Applying 
two-dimensional PCA, there was no global difference between mIMCD-3 cells and iRECs. Hence, pooled sam-
ples serving as quality control were centered between the four groups and had low intra-group variance. In PC3, 
iRECs and mIMCD-3 cells were separated with 9.5% of all differences occurred (Fig. 1b).
Figure 2 shows a heat map of metabolites with an FDR-corrected q-value < 0.05 (all ANOVA and Tukey’s HSD 
results are shown in supplementary Table S6). The main differences were observed between kidney lysates and 
cultured cells as shown by Ward clustering. These alterations are also representing the discrimination of kidney 
tissue to cell culture samples by PC1 (Fig. 1a). The contributing metabolites were products or intermediates of 
organismal catabolism like urea, 3-sulfinoalanine or modified nucleosides as well as typical animal fatty acids like 
arachidonic acid, linoleic acid or palmitoleic acid which are either uniquely present or higher abundant in kidney 
tissue than in cultured cells. Additionally, the metabolic extract was higher concentrated using kidneys compared 
to cells obtained from culture and thus more metabolites were detected in kidneys, which were below the detec-
tion limit in cell culture. This group mainly consisted of nucleosides and nucleobases.
Figure 1. iRECs are similar to other renal epithelial cells and differ significantly from MEFs. (a) PCA of 
endometabolite profiling with PC1 against PC2. (b) PCA of endometabolite profiling with PC2 against PC3. 
blue: MEFs, red: mIMCD-3 cells, green: iRECs, orange: pooled quality control sample, each n = 3; turquoise: 
whole kidneys, n = 6. Replicates are highlighted as individual dots, shaded area shows the 95%-confidence 
interval.
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The heat map also shows the different clusters distinguishing cell types. Here, the differences were not based 
on cell type specific metabolites but different concentration ratios and included mainly amino acids, sugars and 
organic acids and their related metabolites. In MEF cells, metabolites involved in sugar and energy metabolism 
were in general strikingly different to mIMCD-3 cells as well as iRECs. These clusters consist, among others, 
of glyceric acid-3-phosphate, lactate, citrate and fumarate. This result might reflect the high energy demand of 
kidney cells. Interestingly, iRECs and mIMCD3 cells are mainly discriminated by increased concentrations of 
biogenic amines such as beta-alanine, putrescine or spermidine in iRECs as well as increased concentrations of 
sugars in mIMCD-3 cells.
Exometabolic profiles showed clustering between mIMCD-3 cells and iRECs but not MEFs. To 
explore whether mIMCD-3 cells and iRECs also behave similarly in their excreted metabolites, cell culture 
medium was analyzed. Due to the analysis of cell culture medium, no data is available for the exometabolome of 
whole kidneys. PCA revealed discrimination between cell- conditioned and unused medium in PC1 as expected 
(Fig. 3a). PC2 showed a significant difference between cultured kidney cells and fibroblasts. Hence, we could not 
detect a difference between iRECs and mIMCD-3 cells in any PC dimension (Fig. 3). Figure 4 shows the corre-
sponding heat map with significantly altered metabolites according to FDR-corrected q-values from ANOVA. 
Unused medium was not considered in the ANOVA to highlight only those metabolites which actually differed 
between the cell types. Two clusters lead to the difference between MEFs and kidney cells: the first one is com-
posed of glucose and amino acids and their relatives which were higher in MEF medium. The second cluster 
consists of glycolysis and TCA-cycle intermediates which were decreased in MEF medium. Nevertheless, some 
differences between mIMCD-3 cells and iRECs regarding the amino acids and their derivatives, succinic acid and 
2-oxoglutaric acid were detected.
Figure 2. Heat map and cluster analysis of endometabolites reveal similarity between renal epithelial cells. 
Range-scaled Z-scores of annotated features with a q-value < 0.05 according to ANOVA and FDR correction. 
Differently abundant metabolite clusters after Pearson and Ward reflect the similarity between cultured renal 
epithelial cells and iRECs in comparison to MEFs. Marked differences are observable between cultured cells and 
primary tissue. blue: MEFs, red: mIMCD-3 cells, green: iRECs, each n = 3; turquoise: whole kidneys, n = 6. a: 
not significant after Tukey’s HSC post-hoc analysis.
www.nature.com/scientificreports/
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Endometabolome changed upon Cisplatin treatment in iRECs and mIMCD-3 cells but not in 
MEFs. To further test the suitability of iRECs as an in vitro model for renal epithelial cells, we tested the 
impact of cisplatin on MEFs, mIMCD-3 cells and iRECs. Due to its long use as a chemotherapeutic agent and 
its dose limiting nephrotoxicity, cisplatin is well studied in in vivo animal models and metabolically well charac-
terized27,35–40. As can be seen in the PCA, cisplatin had no global effect on MEFs, neither in PC1, PC2 nor PC3 
(Fig. 5). However, cisplatin induced metabolic alterations in kidney cells which could be observed in PC1 as 
well as in PC2 (Fig. 5a). PC3 did not discriminate between cisplatin treated and non-treated cells but iRECs and 
mIMCD-3 cells (Fig. 5b).
The heat map shows significantly altered metabolites of the endometabolome (Fig. 6). In MEFs, the two main 
clusters of either highly abundant or lowly abundant metabolites did not change after cisplatin treatment. In 
contrast, the main clusters of renal epithelial cells changed in response to cisplatin. After cisplatin treatment, a 
concomitant decrease in many metabolites was observed including many amino acids as well as glycolysis, pen-
tose monophosphate pathway and TCA-cycle intermediates. One cluster showed an increase of metabolites after 
cisplatin treatment that was only observed in iRECs. Contributing features were medium-chain and large-chain 
Figure 3. Exometabolites from iRECs are similar to those from mIMCD-3 cell medium and not to MEF 
medium. (a) PCA of exometabolite profiling with PC1 against PC2. (b) PCA of exometabolite profiling with 
PC2 against PC3. blue: MEFs, red: mIMCD-3 cells, green: iRECs, pink: blank medium, orange: pooled quality 
control sample, each n = 3. Replicates are represented by individual dots, shaded area shows the 95%-confidence 
interval.
Figure 4. Heat map and cluster analysis of exometabolome. Range-scaled Z-scores of annotated features with 
q-value < 0.05 according to ANOVA and FDR. Differently abundant metabolite clusters after Pearson and Ward 
reflect the similarity between mIMCD-3 cells and iRECs in comparison to MEFs. blue: MEFs, red: mIMCD-3 
cells, green: iRECs, pink: blank medium, each n = 3.
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fatty acids, as well as glucose. At the bottom of the heat map, minor clusters appeared which showed differences 
between mIMCD-3 cells and iRECs independently of cisplatin, and an increase of metabolites induced by cis-
platin specifically in mIMCD-3 cells. To determine which pathways were particularly affected, we performed a 
pathway analysis comparing the specific impact of cisplatin in the three cell lines. While no significant alteration 
occurred in MEFs, several pathways were affected in both mIMCD-3 cells and iRECs. This analysis confirmed the 
results from the heat map as several amino acid pathways, glycolysis, TCA-cycle and some lipid pathways were 
significantly altered (see supplementary Table S7). As the key alterations changed after cisplatin application could 
be detected in amino acid and energy metabolism, we performed a targeted LC/MS analysis for amino acids and 
intermediates of glycolysis and the TCA-cycle. Whereas no significant alteration was observed in MEFs, in both 
mIMCD-3 cells and iRECs amino acids and energy metabolites were drastically decreased. Glucose accumulation 
could only be validated in iRECs, although an insignificant trend could also be observed in mIMCD-3 cells (see 
supplementary Fig. S1 and supplementary Table S6). The clustering confirmed the discrimination between MEFs 
and kidney cells. Moreover, the impact of cisplatin on the metabolome of renal cells led to a more prominent 
discrimination than the two renal cell lines did themselves (see supplementary Fig. S1, top). These results are thus 
consistent with the untargeted GC/MS analysis.
To test which metabolites contributed most to the alteration by cisplatin in iRECs, a VIP plot was calcu-
lated (detailed results are shown in supplementary Table S8). Figure 7 shows all compounds with a VIP score 
above 1. The most important features were intermediates from sugar metabolism as well as hypotaurine, taurine, 
beta-alanine, 5-aminovaleric acid and pyridoxine. Almost all of these metabolites were down regulated.
Exometabolomics revealed impaired amino acid uptake in iRECs by Cisplatin. As shown in 
Fig. 8, global metabolome analysis could not discriminate cisplatin-treated medium from non-treated medium, 
neither in PC1, PC2 nor PC3.
However, restricting the analysis to ANOVA-positive metabolites revealed differences between treated and 
non-treated medium from iRECs and no discrimination within MEF medium or mIMCD-3 cell medium (Fig. 9). 
Contributing metabolites were basically amino acids, which were increased after cisplatin-treatment. Comparison 
to the unused medium indicated that these increases resulted from both elevated excretion and reduced import. 
Additionally, there were significant alterations in specific metabolites like sugars, lactate and ethanolamine.
Consistently, targeted validation of the exometabolome by LC/MS led to less prominent results than the tar-
geted endometabolome analysis. No significant alterations were observed in the medium of MEFs and only ser-
ine was significantly upregulated in the medium of mIMCD-3 cells. In iRECs medium, serine and cystine were 
upregulated while glycolysis intermediates pyruvate and lactate were decreased upon cisplatin treatment (see 
supplementary Fig. S2).
Discussion
In this study, directly reprogrammed renal epithelial cells were characterized by untargeted metabolomics for the 
first time. By this approach, we could successfully show that the metabolic profile of iRECs is strikingly similar 
to that of cultured renal epithelial cells (mIMCD-3 cells). Importantly, cluster analysis could clearly discriminate 
iRECs from those cells they were derived from (MEFs). The similarity was not only shown by endometabolite 
profiling but also by analyzing the exometabolome.
Figure 5. Cisplatin affects the endometabolome exclusively in renal epithelial cells and iRECs. (a) PCA 
of endometabolite profiling with PC1 against PC2. (b) PCA of endometabolite profiling with PC2 against 
PC3. light color: untreated, dark color: cisplatin-treated; blue: MEFs, red: mIMCD-3 cells, green: iRECs, 
orange: pooled quality control sample, each n = 3. Each dot represents a replicate, shaded area shows the 
95%-confidence interval.
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To further functionally test the metabolome of iRECs, we applied a well-described nephrotoxic drug, cispla-
tin, to MEFs, iRECs and mIMCD-3 cells. Global endometabolome analysis revealed significant alterations in 
the metabolome of mIMCD-3 cells and iRECs upon cisplatin treatment whereas no effects could be observed 
Figure 6. Heat map and cluster analysis of endometabolome discriminates cisplatin treatment only in renal 
epithelial cells. Range-scaled Z-scores of annotated features with a q-value < 0.05 according to ANOVA and 
FDR. No effect could be observed in MEFs after cisplatin application, while there was a strong influence on 
renal epithelial cells. Amino acids and intermediates of glycolysis, TCA-cycle and pentose phosphate pathway 
were concomitantly down regulated by cisplatin in iRECs and mIMCD-3 cells, whereas fatty acid accumulation 
was unique to iRECs. light color: untreated, dark color: Cisplatin-treated; blue: MEFs, red: mIMCD-3 cells, 
green: iRECs, each n = 3
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in MEFs. Strikingly, the alterations were thoroughly in line with published in vivo data, including deprivation 
of amino acids27,36 and reduced levels of intermediates of glycolysis, pentose phosphate pathway and citric acid 
cycle44,45. These central findings could be successfully validated by targeted LC/MS analysis of amino acids, glyc-
olysis and TCA-cycle intermediates.
Most interestingly, an accumulation of medium and large chain fatty acids was only observed in iRECs but 
not in mIMCD-3 cells. These alterations also take place in vivo probably by impaired signaling of peroxisome 
Figure 7. Most important metabolites changed by cisplatin in iRECs. All features with a VIP score > 1 between 
cisplatin treated and untreated iRECs are displayed. Relative levels are shown for each feature with high 
abundance (red) and low abundance (green).
Figure 8. Cisplatin does not influence the exometabolome globally. (a) Principal component analysis of 
exometabolite profiling with PC1 against PC2. (b) PCA of exometabolite profiling with PC2 against PC3. light 
color: untreated, dark color: cisplatin-treated; blue: MEFs, red: mIMCD-3 cells, green: iRECs, orange: pooled 
quality control sample, each n = 3. Each dot represents a replicate, shaded area shows the 95%-confidence 
interval.
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proliferator-activated receptor-α (PPAR-α)37,59,60, due to direct cisplatin-mediated inhibition of PPAR-α DNA- 
binding activity61. Consequently, the PPAR-α target gene, mitochondrial medium-chain acyl-CoA dehydroge-
nase (MCAD), one important enzyme in fatty acid oxidation, was less expressed in cisplatin- treated mice62. 
Consistently, PPAR-α activators lead to elevated MCAD mRNA levels and enzyme activity62 and to reduced fatty 
acid accumulation after cisplatin treatment37,60. In kidney tissue and serum of mice treated with cisplatin and the 
PPAR-α ligand WY, levels of non-esterified fatty acids and triacylglycerols were significantly reduced in contrast 
to mice treated with cisplatin only. Moreover, treatment with the PPAR-α ligand WY prevented acute renal failure 
after cisplatin exposure62. These observations suggest that the accumulation of fatty acids we observed in iRECs 
plays a significant pathophysiological role in cisplatin- mediated nephrotoxicity.
In addition, exometabolome analysis revealed an increase in amino acids in the medium of iRECs but neither 
in mIMCD-3 cells nor MEFs. This is again consistent with aminoaciduria observed in vivo27,36,37. Targeted LC/MS 
validation revealed more significant alterations in the medium of iRECs than in the medium of mIMCD-3 cells 
and MEFs, including amino acids and metabolites of energy metabolism.
Analysis of metabolites most significantly changed upon cisplatin treatment in the endometabolome of iRECs 
uncovered substances, to which beneficial effects against cisplatin-induced nephrotoxicity have been attributed. 
These included taurine, pyridoxine and beta-alanine (the latter administered as N-benzoyl-beta-alanine)63–65. 
In summary, our findings suggest that iRECs faithfully reflect many pathophysiological responses to cisplatin. If 
metabolomic profiling of iRECs represents a good in vitro model system for nephrotoxicity testing, will need to 
be confirmed by testing additional nephrotoxic substances.
The possibility to reprogram human fibroblasts to hiRECs8 offers the opportunity to test nephrotoxic agents 
individually for patients or in a disease specific background. Untargeted metabolomics is not only an excellent 
technique to test the response of iRECs to new drugs as a risk assessment for potential nephrotoxic side effects, 
but could also be used to discover agents preventing or attenuating nephrotoxicity of substances in clinical use.
Figure 9. Heat map and cluster analysis of exometabolome after cisplatin-treatment. Range-scaled Z-scores 
of annotated features with a q-value < 0.05 according to ANOVA and FDR. Medium was excluded for the 
statistical analysis. No effect could be observed by cisplatin application on MEF and mIMCD-3 medium as there 
was clustering between both untreated and cisplatin-treated groups. However, clustering differentiated between 
the medium of treated and non-treated iRECs. Amino acids and their derivatives as well as sugars and lactate 
were mainly affected. light color: untreated, dark color: cisplatin-treated; blue: MEFs, red: mIMCD-3 cells, 
green: iRECs, each n = 3.
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